Pharma News - Chemdiv

FDA Withdraws Umbralisib Due to Elevated Mortality Risk

The FDA announced that it has withdrawn approval for umbralisib (Ukoniq, TG Therapeutics), based on an updated analysis of the phase 3 UNITY-CLL clinical trial, which continues to show “a possibl...

Study Supports Paxlovid’s Efficacy Against COVID-19 and Omicron Variant

Pfizer’s Paxlovid (nirmatrelvir, ritonavir) significantly reduced the risk of severe COVID-19 infection or mortality, Israeli researchers reported.

FDA Approves First Measles Vaccine in Half a Century

GSK shared exciting news Monday morning, announcing that the company’s vaccine for protection against measles, mumps and rubella (MMR) has been approved by the U.S. Food and Drug Administration.&...

BMS Picks up High Potential NSCLC Drug in $4.1B Turning Point Acquisition

Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.

Roche, Repare Ink $1.2B Deal for Development of Cancer Therapy

Shares of Repare Therapeutics are soaring more than 27% in premarket trading following the announcement Wednesday of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma gi...

FDA grants Fast Track Designation to mocravimod with HSCT for acute myeloid leukemia

The FDA granted fast track designation to mocravimod in combination with allogeneic hematopoietic stem cell transplantation for post-remission therapy of acute myeloid leukemia. ...

US FDA grants fast track designation to Midatech Pharma’s MTX110 to treat recurrent glioblastoma

Midatech Pharma PLC, an R&D biotechnology company, announced that upon submitting an application to the US Food and Drug Administration (FDA), its development programme of MTX110 for the treatm...

NICE Recommends UCB’s Fintepla for Dravet Syndrome-Related Seizures

The UK’s National Institute for Healthcare Excellence (NICE) has recommended UCB’s Fintepla (fenfluramine) for National Health Service (NHS) use in patients with Dravet syndrome-associated seiz...

Chemical inhibitor blocks final path to cell death in mice with Parkinson's symptoms

In studies in mice, Johns Hopkins Medicine researchers say they have identified a chemical compound that stops the final events in the pathway linked to the death of brain cells in Parkinson's dise...

Astellas’ subsidiary, Xyphos & GO Therapeutics ink research and license agreement to develop novel antibodies for immuno-oncology

Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, Xyphos) and GO have entered into a strategic research collaboration a...

WHO says monkeypox has been spreading undetected as global cases rise to more than 550

The World Health Organization on Wednesday confirmed more than 550 monkeypox cases across 30 countries as the virus continues to spread across the globe.

FDA Pulls Approval for TG Therapeutics' Cancer Drug

Shares of TG Therapeutics are falling fast in Wednesday trading after the U.S. Food and Drug Administration announced it was pulling approval of the cancer drug Ukoniq (umbralisib).

Pharma News, 2022